Choice of Drugs for Short Course Chemotherapy

  • D. A. Mitchison
Part of the Chemotherapy book series (CT, volume 3)


The concept that the duration of chemotherapy for tuberculosis might be drastically shortened has arisen from a considerable body of experimental evidence. I am going to review this evidence, describe how it leads to a choice of regimens for clinical studies in man and also discuss why some of the drugs are particularly effective.


Viable Count Pasteur Institute Strain H37Rv British Medical Research Council Royal Postgraduate Medical School 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Dickinson, J.M., and Mitchison, D.A., Tubercle, 1970a, 51, 82.PubMedCrossRefGoogle Scholar
  2. Dickinson, J.M., and Mitchison, D.A., Tubercle, 1970b, 51, 389.PubMedCrossRefGoogle Scholar
  3. Fox, W., and Mitchison, D.A., Amer. Rev. Resp. Dis., 1975, 111, 325PubMedGoogle Scholar
  4. Grumbach, F., Canetti, G., and Le Lirzin, M., Tubercle, 1969, 50, 280.PubMedCrossRefGoogle Scholar
  5. Le Lirzin, M., Ciba Foundation Symposium: Rifampicin and current policies in antituberculosis chemotherapy, Ciba Laboratories, 1972, p. 7.Google Scholar
  6. McCune, R.M., Feldmann, F.M., Lambert, H.P., and McDermott, W., J. exp. Med., 1966, 123, 445.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1976

Authors and Affiliations

  • D. A. Mitchison
    • 1
  1. 1.British Medical Research Council, Unit for Laboratory Studies of TuberculosisRoyal Postgraduate Medical SchoolLondonUK

Personalised recommendations